ข่าวประชาสัมพันธ์ Cytocell Ltd+Lung Cancer

Cytocell Ltd Introduces New ROS1 Genetic Test for Non-Small-Cell Lung Cancer

Cytocell Ltd. today announced the availability of a new molecular cytogenetic test designed to identify the presence of gene rearrangements associated with a specific form of non-small-cell lung cancer (NSCLC). These rearrangements in a gene known as ROS1 (c-ros oncogene 1) have been implicated in the formation of cancerous tumors in patients with NSCLC. (Logo: http://photos.prnewswire.com/prnh/20120906/559436 ) Lung cancer is the world's leading cause of cancer death with more than 1.6 million

Nearly 80% of Doctors Worldwide Mistakenly Believe Nicotine Causes Lung Cancer, Thwarting Efforts to Help One Billion Smokers Quit

Survey of more than 15,000 physicians in 11 countries uncovers need for further educationThe Foundation for a Smoke-Free World invites researchers to propose new analysis...

วันมะเร็งปอดโลกซึ่งตรงกับวันที่ตรงกับวันท... เสวนาวันมะเร็งปอดโลก: ดูแลปอด ดูแลใจ เพื่อผู้ป่วยมะเร็งปอด — วันมะเร็งปอดโลกซึ่งตรงกับวันที่ตรงกับวันที่ 1 สิงหาคมของทุกปี จัดขึ้นเพื่อรณรงค์ให้คนทั่วโลกห...

Thai Lung Cancer Group (TLCG) organizes t... TLCG organizes the "Innovations for Thai Lung Cancer Patients 2020" with the launch "LungAndMe" — Thai Lung Cancer Group (TLCG) organizes the "Innovations...

Innovations for Thai Lung Cancer Patients... Innovations for Thai Lung Cancer Patients 2020 launch "LungAndMe" — Innovations for Thai Lung Cancer Patients 2020: evolving treatments for lung cancerBri...

Merck and Pfizer Provide Update on Phase III JAVELIN Lung 200 Trial of Avelumab Monotherapy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Not intended for UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced results from the Phase III JAVELIN Lung 200 trial...

โรงพยาบาลวัฒโนสถ ขอเชิญชวนผู้ที่สนใจตรวจส... โรงพยาบาลวัฒโนสถเชิญชวนตรวจมะเร็งปอดเนื่องในวันงดสูบบุหรี่โลก (Package Lung Cancer Early Detection ) — โรงพยาบาลวัฒโนสถ ขอเชิญชวนผู้ที่สนใจตรวจสุขภาพ "ป้อ...

Registration & Abstract Submission Open for IASLC's 2016 World Conference on Lung Cancer in Vienna

Largest Worldwide Lung Cancer Research Organization Invites Global Collaborators to Attend Registration and abstract submission is now open for the International Association for the Study of Lung Cancer...

Global Strategic Partners Merck and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer

Not intended for UK-based media First of several registration trials expected to start in 2015 for the alliance between Merck and Pfizer Initiation and first...

Merck Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer

Not intended for UK-based media Merck announced today that its biopharmaceutical division Merck Serono will discontinue the clinical development program of its investigational MUC1...

Lung Cancer Stage Four 10 Years Cancer-Free Through Non-toxic Alternative Cancer Treatment

Recurrent lung cancer responds to Integrative Immunotherapy Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis....

Merck Serono Announces New Publication of Results of the Phase III START Trial Investigating Tecemotide in Non-Small Cell Lung Cancer in The Lancet Oncology

Publication offers detailed results of START, including an exploratory analysis of the clinically meaningful survival prolongation with...

Cytocell Ltd เปิดตัวสาร FISH ชุดใหม่สำหรับตรวจสอบโรคมะเร็งเม็ดเลือดขาวเรื้อรังแบบลิมฟอยด์

บริษัท ไซโตเซลล์ (Cytocell Ltd.) ประกาศเปิดตัวชุดตรวจสอบวิเคราะห์เซลล์ในสภาพแวดล้อมแบบจำลองชุดใหม่สำหรับตรวจหาโรคมะเร็งเม็ดเลือดขาวเรื้อรัง (CLL) แบบลิมฟอยด์ในผู้ป่วย (โลโก้: http://photos.prnewswire.com/prnh...

Cytocell Ltd Introduces New Haematology FISH Probes for Chronic Lymphocytic Leukaemia (CLL)

Cytocell Ltd. announced the availability of a new range of in vitro diagnostic tests to aid in detecting patients with Chronic Lymphocytic Leukaemia (CLL), a cancer of the lymphocytes. (Logo: http://photos...

ALIMTA(R) Label Update Approved by European Commission to Reflect Significant Overall Survival Benefits for Specific Lung Cancer Patients

Eli Lilly and Company (NYSE: LLY) announced today that the European Commission has approved an update to the label for ALIMTA(R) (pemetrexed for injection), adding...

Avastin Shows Longest Overall Survival for Patients With Adenocarcinoma, the Most Common Type of Advanced Lung Cancer

This update outlines data from a preplanned analysis of the pivotal E4599 study in patients with non-small cell lung cancer (NSCLC), published in the Journal of Thoracic Oncology. The...

Large 'Real-World' Study Shows Avastin-based Therapy Extends Survival Beyond Fourteen Months in Patients With Advanced Lung Cancer

- For non-US, non-UK Media Only - Avastin Benefits Demonstrated in Combination With a Wide Range of Chemotherapies and in a Broad Patient Population New data show that...

Tarceva Helps Patients With Genetically Distinct Form of Lung Cancer Live Longer

- For non-US, non-UK Media Only - Phase II Study Points to Importance of EGFR Biomarker to Identify Patients who can Gain Exceptional Survival BenefitsNew data show that first-line treatment with Tarceva(R)(erlotinib)...

Tarceva Receives Positive Opinion in Europe for Maintenance Treatment of Advanced Lung Cancer

- Approval Would Allow Patients to Benefit From Earlier Use of Well-Tolerated Oral Treatment Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Committee for Medicinal Products for Human...

วันมะเร็งปอด Lung Cancer Day

โรงพยาบาลไทยนครินทร์ จัดกิจกรรมรณรงค์เนื่องในวันมะเร็งปอด หรือ Lung Cancer Day ภายในงานได้มีการจัดบอร์ดนิทรรศการให้ความรู้การดูแลตนเองให้ห่างไกลจากโรคมะเร็งปอดและตั้งจุดบริการสืบค้นโอกาสเสี่ยงโดยใช้โปรแกรม Family Tree ผ่านระบบคอมพิวเตอร์ (จากภาพ) นพ.เจริญ มีนสุข...

Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

Data from the Phase III ZODIAC(1) study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were...

Maintenance Treatment With Avastin and Tarceva in Combination Helps Lung Cancer Patients Live Longer Without Their Disease Worsening

- Phase III ATLAS Study Achieves a New Milestone in Treating Advanced Lung Cancer Roche announced today that the Phase III ATLAS study showed patients with advanced non...

AsiaNet Daily Summary - Press Releases for Monday April 27, 2009

ROCHE ANNOUNCES... BASEL: Roche and the Spanish Lung Cancer Group (SLCG) Friday announced their collaboration on the first phase III trial to investigate Tarceva (erlotinib) in lung cancer patients with genetic mutations in their...

Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer

- New Phase III Study Will Evaluate if Tarceva is Superior to Traditional Chemotherapy in First Line Treatment of key Group of Patients Roche and the Spanish Lung Cancer Group (SLCG) today announced their...